

Stefan Zimmermann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4101188/publications.pdf>

Version: 2024-02-01

18
papers

922
citations

1040056

9
h-index

940533

16
g-index

19
all docs

19
docs citations

19
times ranked

1786
citing authors

#	ARTICLE	IF	CITATIONS
1	Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. <i>Cancer Discovery</i> , 2022, 12, 108-133.	9.4	165
2	Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug-drug interactions. <i>Cancer Treatment Reviews</i> , 2014, 40, 917-926.	7.7	134
3	Turning up the heat on non-immunoreactive tumours: opportunities for clinical development. <i>Lancet Oncology</i> , The, 2020, 21, e419-e430.	10.7	128
4	Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases. <i>Cancer Treatment Reviews</i> , 2014, 40, 716-722.	7.7	123
5	Ovarian Cancer Immunotherapy: Turning up the Heat. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2927.	4.1	116
6	A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy. , 2018, 6, 156.		58
7	Safety and Tolerability of Adoptive Cell Therapy in Cancer. <i>Drug Safety</i> , 2019, 42, 315-334.	3.2	57
8	Targeted therapy in NSCLC driven by HER2 insertions. <i>Translational Lung Cancer Research</i> , 2014, 3, 84-8.	2.8	52
9	Immune Checkpoint Inhibitors in the Management of Lung Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 682-695.	3.8	35
10	Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy. <i>Current Treatment Options in Oncology</i> , 2018, 19, 37.	3.0	13
11	Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment. <i>Cytotherapy</i> , 2020, 22, 780-791.	0.7	9
12	Investigating Barriers in HIV-Testing Oncology Patients: The IBITOP Study, Phase I. <i>Oncologist</i> , 2016, 21, 1176-1182.	3.7	7
13	Delineating the Role of PD-1/PD-L1 Blockade in Advanced SCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1242-1244.	1.1	7
14	Appraising the Tail of the Survival Curve in the Era of PD-1/PD-L1 Checkpoint Blockade. <i>JAMA Oncology</i> , 2019, 5, 1403.	7.1	7
15	Investigating barriers in HIV-testing oncology patients. The IBITOP study: phase I. <i>Journal of the International AIDS Society</i> , 2014, 17, 19622.	3.0	3
16	Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes. , 2020, 8, e001155.		3
17	Practical tips and tricks with recently approved molecular targeted agents in non-small-cell lung cancer. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 307-309.	2.2	1
18	In-depth immune and molecular profiling of melanoma patients receiving adoptive T-cell therapy reveals biomarkers of efficacy in ATATIL study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2533-2533.	1.6	0